Chimerix to Report Third Quarter 2024 Financial Results and Provide an Operational Update on November 7, 2024
Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on developing life-saving medicines, has scheduled a conference call and audio webcast for November 7, 2024, at 8:30 a.m. ET. During this event, the company will present its third quarter 2024 financial results and provide a business update. Participants can join via phone at (646) 307-1963 (domestic) or (800) 715-9871 (international) using conference ID 6580777. A live webcast will be available on the company's website, with an archived version accessible approximately two hours after the event.
Chimerix (NASDAQ:CMRX), una compagnia biofarmaceutica focalizzata nello sviluppo di medicine salvavita, ha programmato una conferenza telefonica e un webcast audio per il 7 novembre 2024, alle 8:30 a.m. ET. Durante questo evento, la compagnia presenterà i suoi risultati finanziari del terzo trimestre 2024 e fornirà un aggiornamento aziendale. I partecipanti possono unirsi tramite telefono al (646) 307-1963 (nazionale) o al (800) 715-9871 (internazionale) utilizzando l'ID della conferenza 6580777. Un webcast dal vivo sarà disponibile sul sito web della compagnia, con una versione archiviata accessibile circa due ore dopo l'evento.
Chimerix (NASDAQ:CMRX), una empresa biofarmacéutica centrada en el desarrollo de medicamentos que salvan vidas, ha programado una conferencia telefónica y una transmisión de audio para el 7 de noviembre de 2024, a las 8:30 a.m. ET. Durante este evento, la empresa presentará sus resultados financieros del tercer trimestre de 2024 y proporcionará una actualización sobre el negocio. Los participantes pueden unirse por teléfono al (646) 307-1963 (nacional) o al (800) 715-9871 (internacional) utilizando el ID de la conferencia 6580777. Habrá una transmisión en vivo disponible en el sitio web de la empresa, con una versión archivada accesible aproximadamente dos horas después del evento.
Chimerix (NASDAQ:CMRX), 생명을 구하는 의약품 개발에 중점을 둔 생물약제 회사가 2024년 11월 7일 오전 8:30 ET에 컨퍼런스 콜 및 오디오 웹캐스트를 예약했습니다. 이 행사에서 회사는 2024년 3분기 재무 결과를 발표하고 비즈니스 업데이트를 제공할 예정입니다. 참가자는 전화로 (646) 307-1963 (국내) 또는 (800) 715-9871 (국제)에 접속하여 컨퍼런스 ID 6580777을 사용하여 참여할 수 있습니다. 이벤트 후 약 두 시간 후에 회사 웹사이트에서 아카이브 버전을 이용할 수 있는 라이브 웹캐스트가 제공됩니다.
Chimerix (NASDAQ:CMRX), une entreprise biopharmaceutique axée sur le développement de médicaments salvateurs, a prévu une conférence téléphonique et un webinaire audio pour le 7 novembre 2024 à 8h30 ET. Lors de cet événement, l'entreprise présentera ses résultats financiers du troisième trimestre 2024 et fournira une mise à jour sur son activité. Les participants peuvent rejoindre par téléphone au (646) 307-1963 (national) ou au (800) 715-9871 (international), en utilisant l'ID de conférence 6580777. Un webinaire en direct sera disponible sur le site de l'entreprise, avec une version archivée accessible environ deux heures après l'événement.
Chimerix (NASDAQ:CMRX), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung lebensrettender Medikamente konzentriert, hat für den 7. November 2024 um 8:30 Uhr ET eine Telefonkonferenz und einen Audio-Webcast angesetzt. Während dieser Veranstaltung wird das Unternehmen seine Finanzergebnisse des dritten Quartals 2024 präsentieren und ein Update zur Geschäftslage geben. Die Teilnehmer können telefonisch unter (646) 307-1963 (inland) oder (800) 715-9871 (international) mit der Konferenz-ID 6580777 teilnehmen. Ein Live-Webcast wird auf der Website des Unternehmens verfügbar sein, und eine archivierte Version wird voraussichtlich etwa zwei Stunden nach der Veranstaltung zugänglich sein.
- None.
- None.
DURHAM, N.C., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Thursday, November 7, 2024 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2024, and to provide a business overview.
To access the live conference call, please dial (646) 307-1963 (domestic) or (800) 715-9871 (international) at least five minutes prior to the start time and refer to conference ID 6580777. A live audio webcast of the call will also be available on the Investors’ section of the Company's website, www.chimerix.com. An archived webcast will be available on the Chimerix website approximately two hours after the event.
About Chimerix
Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company’s most advanced clinical-stage development program, dordaviprone (ONC201), is in development for H3 K27M-mutant diffuse glioma. The Company is conducting Phase 1 dose escalation studies of ONC206 to evaluate safety and PK data.
CONTACT:
Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com
FAQ
When will Chimerix (CMRX) report Q3 2024 earnings?
How can I access Chimerix's (CMRX) Q3 2024 earnings call?
Where can I find the replay of Chimerix's (CMRX) Q3 2024 earnings webcast?
